Navigation Links
Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
Date:1/14/2010

ABBOTT PARK, Ill., Jan. 14 /PRNewswire-FirstCall/ -- A new diagnostic tool, which studies show can aid in determining the risk of whether a pelvic mass is benign or malignant, is now available in Europe. This simple blood test is expected to help in the assessment of epithelial ovarian cancer, the most lethal form of gynecological cancer. This important immunoassay, which will run on Abbott's ARCHITECT systems, is the first automated HE4 test available anywhere in the world.

Research has shown that this novel diagnostic marker, combined with other tests such as the CA125 assay, can aid in measuring the risk of epithelial ovarian cancer in pre- and post-menopausal women who have a pelvic mass.

According to the International Agency for Research on Cancer, the five-year survival rate of ovarian cancer patients is 46 percent. However, when the disease is diagnosed earlier, the survival rate increases to 94 percent.

"The ability of this test to help physicians predict whether a pelvic mass is benign or malignant is an important development for both patients and physicians," said Michael Warmuth, senior vice president, diagnostics, Abbott. "Abbott's ARCHITECT HE4 test will aid physicians in determining the most appropriate treatment for their patients."

Abbott partnered with Fujirebio Diagnostics, Inc. in the development of the assay. The test is now available in several European countries, as well as in some countries in Asia Pacific and Latin America. The ARCHITECT HE4 Assay was recently submitted to the FDA for 510(k) clearance.

About Ovarian Cancer

Ovarian cancer is the leading cause of death from gynecological cancers and the fifth-leading cause of cancer death in women. An estimated one in 72 women will develop ovarian cancer in her lifetime. It accounts for 31 percent of cancers of the female genital organs. Women who are postmenopausal are at the greatest risk for ovarian cancer.

About Abbott Diagnostics

Abbott Diagnostics is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, blood banks, physician offices and clinics. With more than 69,000 institutional customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, cost effectiveness and flexibility. The history of Abbott Diagnostics is filled with examples of first-of-a-kind products and significant technological advancements, including the development of the very first diagnostic test to detect HIV.

About Abbott

Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

SOURCE Abbott

RELATED LINKS
http://www.abbott.com

'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Abbott to Provide $1 Million in Funding, Products to Help Address Health Needs in Haiti
2. Feeding America and Abbott Transform Disaster Preparedness Into Hunger Relief
3. Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems
4. Abbott Declares 344th Consecutive Quarterly Dividend
5. Abbott Statement on ARBITER 6 - HALTS Results and Abbotts Niaspan (niacin extended-release)
6. Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
7. Abbott Receives Sustainability Award for Continued Efforts to Protect the Environment in Illinois
8. Abbott Again Honored for Offering One of the Top 10 Leading Workplaces
9. Abbott Receives FDA Approval for First Fully Automated Blood Screening Test for HIV-1/HIV-2
10. Abbott Announces TCT 2009 Activities
11. Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... Improvements Act of 1976, as amended ("HSR"), with respect ... Nasdaq: CPXX ) expired effective June 24, ... As previously announced on May 31, 2016, Jazz Pharmaceuticals ... which Jazz Pharmaceuticals has commenced a tender offer for ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology: